APC mutations, TP53 mutations, and cancer cell lines from GI, breast, gynecologic (GYN), hematologic (Hema), genitourinary (GU), and other cancer cell lineages were used to match MSI (n = 75) and MSS (n = 225) cancers. This evidence concerns the gene TP53 and cancer.